Corcept Therapeutics Shareholder Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy CORT?
Source: Globenewswire
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics investors that the deadline to apply for Lead Plaintiff is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- False Statements Allegation: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose significant FDA concerns regarding the efficacy data of its lead drug candidate, Relacorilant, resulting in substantial investor losses.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market pessimism about the company's prospects.
- Information Gap Issue: Hagens Berman's partner highlighted a critical information gap between what Corcept publicly stated and what the FDA communicated privately, potentially leading investors to misjudge the company's future, thereby exacerbating legal risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 33.820
Low
50.00
Averages
91.00
High
121.00
Current: 33.820
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA GREENLIGHTS CORCEPT'S LIFYORLI™ (RELACORILANT) IN COMBINATION WITH NAB-PACLITAXEL FOR PLATINUM-RESISTANT OVARIAN CANCER TREATMENT
FDA Approval: The FDA has approved Corcept's selective glucocorticoid receptor antagonist, Relacorilant, for the treatment of patients with platinum-resistant ovarian cancer.
Treatment Significance: This approval marks a significant advancement in the treatment options available for patients facing this challenging form of cancer.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- False Statements Allegation: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose significant FDA concerns regarding the efficacy data of its lead drug candidate, Relacorilant, resulting in substantial investor losses.
- Stock Price Crash: Following the announcement on December 31, 2025, that Corcept received a Complete Response Letter from the FDA, the stock plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market pessimism about the company's future.
- Information Gap Issue: Hagens Berman partner Reed Kathrein highlighted a critical information gap between what Corcept publicly stated and what the FDA communicated privately, potentially leading to investor misjudgments about the company's prospects and exacerbating legal risks.
See More
Corcept Therapeutics Receives FDA Approval for Lifyorli
- FDA Approval: Corcept Therapeutics announced that its drug Lifyorli has received FDA approval for treating platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers, marking a significant advancement in the company's cancer treatment portfolio.
- Clinical Trial Success: The approval was based on positive outcomes from the Rosella trial, which involved 381 patients and demonstrated the efficacy of Lifyorli in combination with the chemotherapy drug nab-paclitaxel, enhancing the company's competitive position in the biotech sector.
- Stock Surge: Following the FDA approval announcement, Corcept's stock price surged nearly 20% in one day, elevating the company's market capitalization to $3.6 billion, reflecting strong market confidence in its new therapy.
- Future Growth Potential: CEO Joseph Belanoff emphasized that this approval is an important first step, indicating the company's commitment to exploring new treatment modalities related to cortisol modulation, suggesting potential for more drug approvals in the future.
See More
Corcept Therapeutics Receives FDA Approval for Lifyorli
- FDA Approval: Corcept Therapeutics' Lifyorli has received FDA approval for use in combination with nab-paclitaxel to treat platinum-resistant ovarian cancer, marking a significant advancement in the company's cancer treatment portfolio.
- Stock Surge: Following the FDA approval announcement, Corcept's shares soared nearly 20% in value, reflecting strong market confidence in the new drug's potential and boosting investor sentiment.
- Successful Clinical Trials: The approval was based on the positive outcomes from the Rosella trial involving 381 patients, demonstrating the drug's efficacy in treatment and further solidifying the company's position in the biotech sector.
- Clear Strategic Direction: CEO Joseph Belanoff stated that the approval of Lifyorli is an important first step in exploring new treatment modalities, indicating a continued focus on cortisol modulation strategies and suggesting more potential FDA approvals in the future.
See More
Corcept Therapeutics Receives FDA Approval for Lifyorli
- FDA Approval: Corcept Therapeutics' Lifyorli has received FDA approval for use in combination with nab-paclitaxel to treat platinum-resistant ovarian cancer, marking a significant advancement in the company's cancer treatment portfolio.
- Stock Surge: Following the FDA approval announcement, Corcept's shares soared nearly 20% in value on the same day, reflecting strong market confidence in the new drug's potential and boosting investor sentiment.
- Successful Clinical Trials: The approval was based on the positive outcomes from the Rosella trial involving 381 patients, demonstrating the drug's efficacy in treatment and further validating the company's unique focus on cortisol modulation.
- Future Growth Potential: CEO Joseph Belanoff emphasized that today's approval is just the first step, indicating that the company will continue to explore additional treatment options, with the potential for more FDA approvals in the future to drive long-term growth.
See More
Surge in Options Trading Volume for Marvell Technology
- Surge in Options Volume: Marvell Technology experienced an options trading volume of 160,810 contracts, equating to approximately 16.1 million shares, which represents about 72% of its average daily trading volume of 22.3 million shares over the past month, indicating strong market interest.
- High Strike Price Focus: Notably, the $100 strike call option expiring on March 27, 2026, saw a trading volume of 34,867 contracts today, representing around 3.5 million underlying shares, suggesting investor optimism regarding the stock's future performance.
- Corcept Therapeutics Options Activity: In parallel, Corcept Therapeutics recorded an options trading volume of 10,145 contracts, approximately 1 million shares, which is 71.8% of its average daily trading volume of 1.4 million shares over the past month, highlighting investor interest in this stock as well.
- Strike Price Insights: For the $50 strike call option expiring on April 17, 2026, the trading volume reached 2,322 contracts today, representing about 232,200 underlying shares, further reflecting bullish sentiment in the market for Corcept.
See More
FDA GREENLIGHTS CORCEPT'S LIFYORLI™ (RELACORILANT) IN COMBINATION WITH NAB-PACLITAXEL FOR PLATINUM-RESISTANT OVARIAN CANCER TREATMENT
FDA Approval: The FDA has approved Corcept's selective glucocorticoid receptor antagonist, Relacorilant, for the treatment of patients with platinum-resistant ovarian cancer.
Treatment Significance: This approval marks a significant advancement in the treatment options available for patients facing this challenging form of cancer.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- False Statements Allegation: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose significant FDA concerns regarding the efficacy data of its lead drug candidate, Relacorilant, resulting in substantial investor losses.
- Stock Price Crash: Following the announcement on December 31, 2025, that Corcept received a Complete Response Letter from the FDA, the stock plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market pessimism about the company's future.
- Information Gap Issue: Hagens Berman partner Reed Kathrein highlighted a critical information gap between what Corcept publicly stated and what the FDA communicated privately, potentially leading to investor misjudgments about the company's prospects and exacerbating legal risks.
See More
Corcept Therapeutics Receives FDA Approval for Lifyorli
- FDA Approval: Corcept Therapeutics announced that its drug Lifyorli has received FDA approval for treating platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers, marking a significant advancement in the company's cancer treatment portfolio.
- Clinical Trial Success: The approval was based on positive outcomes from the Rosella trial, which involved 381 patients and demonstrated the efficacy of Lifyorli in combination with the chemotherapy drug nab-paclitaxel, enhancing the company's competitive position in the biotech sector.
- Stock Surge: Following the FDA approval announcement, Corcept's stock price surged nearly 20% in one day, elevating the company's market capitalization to $3.6 billion, reflecting strong market confidence in its new therapy.
- Future Growth Potential: CEO Joseph Belanoff emphasized that this approval is an important first step, indicating the company's commitment to exploring new treatment modalities related to cortisol modulation, suggesting potential for more drug approvals in the future.
See More
Corcept Therapeutics Receives FDA Approval for Lifyorli
- FDA Approval: Corcept Therapeutics' Lifyorli has received FDA approval for use in combination with nab-paclitaxel to treat platinum-resistant ovarian cancer, marking a significant advancement in the company's cancer treatment portfolio.
- Stock Surge: Following the FDA approval announcement, Corcept's shares soared nearly 20% in value, reflecting strong market confidence in the new drug's potential and boosting investor sentiment.
- Successful Clinical Trials: The approval was based on the positive outcomes from the Rosella trial involving 381 patients, demonstrating the drug's efficacy in treatment and further solidifying the company's position in the biotech sector.
- Clear Strategic Direction: CEO Joseph Belanoff stated that the approval of Lifyorli is an important first step in exploring new treatment modalities, indicating a continued focus on cortisol modulation strategies and suggesting more potential FDA approvals in the future.
See More
Corcept Therapeutics Receives FDA Approval for Lifyorli
- FDA Approval: Corcept Therapeutics' Lifyorli has received FDA approval for use in combination with nab-paclitaxel to treat platinum-resistant ovarian cancer, marking a significant advancement in the company's cancer treatment portfolio.
- Stock Surge: Following the FDA approval announcement, Corcept's shares soared nearly 20% in value on the same day, reflecting strong market confidence in the new drug's potential and boosting investor sentiment.
- Successful Clinical Trials: The approval was based on the positive outcomes from the Rosella trial involving 381 patients, demonstrating the drug's efficacy in treatment and further validating the company's unique focus on cortisol modulation.
- Future Growth Potential: CEO Joseph Belanoff emphasized that today's approval is just the first step, indicating that the company will continue to explore additional treatment options, with the potential for more FDA approvals in the future to drive long-term growth.
See More
Surge in Options Trading Volume for Marvell Technology
- Surge in Options Volume: Marvell Technology experienced an options trading volume of 160,810 contracts, equating to approximately 16.1 million shares, which represents about 72% of its average daily trading volume of 22.3 million shares over the past month, indicating strong market interest.
- High Strike Price Focus: Notably, the $100 strike call option expiring on March 27, 2026, saw a trading volume of 34,867 contracts today, representing around 3.5 million underlying shares, suggesting investor optimism regarding the stock's future performance.
- Corcept Therapeutics Options Activity: In parallel, Corcept Therapeutics recorded an options trading volume of 10,145 contracts, approximately 1 million shares, which is 71.8% of its average daily trading volume of 1.4 million shares over the past month, highlighting investor interest in this stock as well.
- Strike Price Insights: For the $50 strike call option expiring on April 17, 2026, the trading volume reached 2,322 contracts today, representing about 232,200 underlying shares, further reflecting bullish sentiment in the market for Corcept.
See More
